Literature DB >> 17762336

The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Peter Goldstraw1, John Crowley, Kari Chansky, Dorothy J Giroux, Patti A Groome, Ramon Rami-Porta, Pieter E Postmus, Valerie Rusch, Leslie Sobin.   

Abstract

INTRODUCTION: The seventh edition of the TNM Classification of Malignant Tumors is due to be published early in 2009. In preparation for this, the International Association for the Study of Lung Cancer established its Lung Cancer Staging Project in 1998. The recommendations of this committee for changes to the T, N, and M descriptors have been published. This report contains the proposals for the new stage groupings.
METHODS: Data were contributed from 46 sources in more than 19 countries. Adequate data were available on 67,725 cases of non-small cell lung cancer treated by all modalities of care between 1990 and 2000. The recommendations for changes to the T, N, and M descriptors were incorporated into TNM subsets. Candidate stage groupings were developed on a training subset and tested in a validation subset.
RESULTS: The suggestions include additional cutoffs for tumor size, with tumors >7 cm moving from T2 to T3; reassigning the category given to additional pulmonary nodules in some locations; and reclassifying pleural effusion as an M descriptor. In addition, it is suggested that T2b N0 M0 cases be moved from stage IB to stage IIA, T2a N1 M0 cases from stage IIB to stage IIA, and T4 N0-1 M0 cases from stage IIIB to stage IIIA.
CONCLUSIONS: Such changes, if accepted, will involve a reassessment of existing treatment algorithms. However, they are based on an intensive and validated analysis of the largest database to date. The proposed changes would improve the alignment of TNM stage with prognosis and, in certain subsets, with treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17762336     DOI: 10.1097/JTO.0b013e31812f3c1a

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  1133 in total

1.  Elevated serum annexin A1 as potential diagnostic marker for lung cancer: a retrospective case-control study.

Authors:  Biaoxue Rong; Chongchong Zhao; Hua Liu; Zongjuan Ming; Xiguang Cai; Wenlong Gao; Shuanying Yang
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

2.  A Case Report of Drug-Induced Myopathy Involving Extraocular Muscles after Combination Therapy with Tremelimumab and Durvalumab for Non-Small Cell Lung Cancer.

Authors:  William Carrera; Brandon J Baartman; Gregory Kosmorsky
Journal:  Neuroophthalmology       Date:  2017-03-15

3.  Assessing the Generalizability of the National Lung Screening Trial: Comparison of Patients with Stage 1 Disease.

Authors:  Nichole T Tanner; Lin Dai; Brett C Bade; Mulugeta Gebregziabher; Gerard A Silvestri
Journal:  Am J Respir Crit Care Med       Date:  2017-09-01       Impact factor: 21.405

4.  Outcomes: wedge resection versus lobectomy for non-small cell lung cancer at the Cancer Centre of Southeastern Ontario 1998-2009.

Authors:  Anna L McGuire; Wilma M Hopman; Dimitri Petsikas; Ken Reid
Journal:  Can J Surg       Date:  2013-12       Impact factor: 2.089

5.  Chart review versus an automated bioinformatic approach to assess real-world crizotinib effectiveness in ALK-positive NSCLC.

Authors:  Nam Bui; Solomon Henry; Douglas Wood; Heather A Wakelee; Joel W Neal
Journal:  JCO Clin Cancer Inform       Date:  2017-03-13

6.  Randomized controlled trials of induction treatment and surgery versus combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: a systematic review and meta-analysis.

Authors:  Zuen Ren; Shijie Zhou; Zhidong Liu; Shaofa Xu
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

7.  Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials.

Authors:  Raymond U Osarogiagbon; Federico Cappuzzo; Tudor Ciuleanu; Larry Leon; Barbara Klughammer
Journal:  Transl Lung Cancer Res       Date:  2015-08

8.  Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities.

Authors:  Ramón Rami-Porta; Hisao Asamura; Peter Goldstraw
Journal:  Transl Lung Cancer Res       Date:  2015-08

9.  Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer.

Authors:  Koko Ishida; Takashi Hirose; Junichi Yokouchi; Yasunari Oki; Sojiro Kusumoto; Tomohide Sugiyama; Hiroo Ishida; Takao Shirai; Masanao Nakashima; Toshimitsu Yamaoka; Tsukasa Ohnishi; Tohru Ohmori; Yoshikazu Kagami
Journal:  Mol Clin Oncol       Date:  2014-02-07

10.  Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced non-small-cell lung cancer: A case series of 20 patients.

Authors:  Jumpei Takeshita; Katsuhiro Masago; Shiro Fujita; Akito Hata; Reiko Kaji; Takahisa Kawamura; Koji Tamai; Takeshi Matsumoto; Kazuma Nagata; Kyoko Otsuka; Atsushi Nakagawa; Kojiro Otsuka; Keisuke Tomii; Takashi Shintani; Kenji Takayama; Masaki Kokubo; Nobuyuki Katakami
Journal:  Mol Clin Oncol       Date:  2014-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.